Oncology Diagnostics Panel Session
Kineticos recently hosted a panel with 3 industry veterans to gain insight regarding the nuances of the oncology diagnostics market. The first installment touched on new, exciting technologies while Part 2 contains insight from our panelists regarding what diagnostic companies can do to monetize their technologies in a time where reimbursement is poor.
Eric Mayer, CEO, EDP Biotech
Sandra Dunn, CEO, Phoenix Molecular
Brian Kelly, Global Director, Diagnostic Partnering, Thermo Fisher
Click here for a condensed and edited version of Part 2.